Mai Capital Management Syndax Pharmaceuticals Inc Transaction History
Mai Capital Management
- $13.2 Billion
- Q4 2024
A detailed history of Mai Capital Management transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Mai Capital Management holds 1,000 shares of SNDX stock, worth $14,750. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000Holding current value
$14,750% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SNDX
# of Institutions
232Shares Held
96.9MCall Options Held
1.39MPut Options Held
543K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$126 Million7.14% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$117 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.95MShares$87.8 Million0.01% of portfolio
-
Morgan Stanley New York, NY5.31MShares$78.4 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$72 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $834M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...